Nichole Tucker

The FDA has granted fast track designation to PRGN-3006 for the treatment of patients with relapsed or refractory cute myeloid leukemia .

The phase 1/2 TakeAim Leukemia study exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been halted by the FDA pending more safety and efficacy data.

The combination of RBN-2397 and pembrolizumab has been dosed in the first patient with squamous cell carcinoma of the lung who is enrolled in a new phase 1b/2 clinical trial.

A survival benefit has been shown in a phase 2 study using intermittent relacorilant and nab-paclitaxel for the treatment of patients with recurrent, platinum-resistant ovarian cancer.

For the second time, an application for approval has been submitted for the FDA for I-omburtamab for the treatment of pediatric patients with central nervous system or leptomeningeal metastasis from neuroblastoma.

The phase 3 ATHENA-MONO trial meet it primary end point of improvement in progression-free survival with rucaparib in patients with newly-diagnosed, advanced ovarian cancer.

Improving gender and racial/ethnic minority inclusion in clinical trials may involve setting an oncology-wide standard.

The FDA has accepted for priority review a new drug application for futibatinib seeking approval for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma who harbor FGFR2 gene rearrangement, including gene fusions.

In an interview with Targeted Oncology, Ravi Salgia, MD, PhD, discussed the research leading to the first-in-human study of LB-100 combined with chemotherapy or immunotherapy to address transformation to small cell lung cancer.

An application for approval has been submitted to the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.

Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

The phase 3 EMERGE-201 for patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient has begun.

The phase 3 CALLA study did not achieve its key end point of progression-free survival improvement with the addition of durvalumab to chemoradiotherapy in patients with locally advanced cervical cancer.

During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.

The FDA is no longer conducting a speedy review of the supplemental biologics license application for luspatercept-aamt as treatment for anemia in adults with non-transfusion-dependent beta thalassemia.

In an interview with Targeted Oncology, C.K. Wang, MD, discussed the importance of real-world data in oncology, the mission of COTA, and research the company has been a part of.

The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.

The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.

Haploidentical donor-derived allogeneic hematopoietic cell transplant appears to be feasible for patients with Philadelphia chromosome-positive chronic myeloid leukemia, similar to other donor types.

Treatment locations in New York, New Jersey, and Florida are recruiting patients with mall cell lung cancer to receive olaparib and low-dose radiotherapy in a phase 1 clinical trial.

In an interview with Targeted Oncology, Charles Geyer, MD, discussed the data from the OlympiA clinical trial and how adjuvant olaparib could impact the treatment of BRCA-positive, HER2-negative breast cancer and other BRCA-positive women’s cancers.

In an interview with Targeted Oncology™, Sumtha K. Pal, discussed the most interesting research presented during ASCO Genitourinary Cancers Symposium.

Tafasitamab-cxi plus lenalidomide has been added to the NCCN Guidelines as a preferred regimen for patients with diffuse large B-cell lymphoma.

Following PERSIST-1 and PERSIST-2 and a recent FDA approval, pacritinib is being investigated in a phase 3 study versus physician's choice of standard therapy in patients with myelofibrosis.

In an interview with Targeted Oncology, Steven M. Albelda, MD, discussed the introduction of chimeric antigen receptor T cells in solid tumor research and how it differs from what has been observed in hematologic malignancies.

Three and a half-year follow-up in the OlympiA trial showed continued survival improvement and underscores the vitality of germline BRCA testing.

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

Adding toripalimab to chemotherapy as frontline treatment for advanced non–small cell lung cancer crossed the boundary for statistical significance in CHOICE-01, meeting 2 study end points.

All primary end points in the phase 3 study of bempegaldesleukin plus nivolumab for the treatment of metastatic melanoma were missed, but analyses are ongoing.